

# Concentration-dependent wrestling between detrimental and protective effects of H<sub>2</sub>O<sub>2</sub> during myocardial ischemia/reperfusion

Z-H Wang<sup>1,2,3</sup>, J-L Liu<sup>1,3</sup>, L Wu<sup>1</sup>, Z Yu<sup>1</sup> and H-T Yang<sup>\*,1</sup>

Reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress are paradoxically implicated in myocardial ischemia/reperfusion (I/R) injury and cardioprotection. However, the precise interpretation for the dual roles of ROS and its relationship with the ER stress during I/R remain elusive. Here we investigated the concentration-dependent effects of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) preconditioning (PC) and postconditioning (PoC) on the ER stress and prosurvival reperfusion injury salvage kinase (RISK) activation using an *ex vivo* rat myocardial I/R model. The effects of H<sub>2</sub>O<sub>2</sub> PC and PoC showed three phases. At a low level (1 μM), H<sub>2</sub>O<sub>2</sub> exacerbated I/R-induced left ventricular (LV) contractile dysfunction and ER stress, as indicated by enhanced phosphorylation of protein kinase-like ER kinase and expressions of glucose-regulated protein 78, X-box-binding protein 1 splicing variant, TNF receptor-associated factor 2, activating transcription factor-6 cleaved 50 kDa fragment, and caspase-12 cleavage, but the I/R-induced RISK activation including protein kinase B (PKB/Akt) and protein kinase Cε (PKCε) remained unchanged. Consistently, the postischemic LV performance in 1 μM H<sub>2</sub>O<sub>2</sub> PC and PoC groups was improved by inhibiting ER stress with 4-phenyl butyric acid but not affected by the ER stress inducer, tunicamycin. At a moderate level (10–100 μM), H<sub>2</sub>O<sub>2</sub> significantly improved postischemic LV performance and enhanced RISK activation, but it did not further alter the ER stress. The cardioprotection but not ER stress was abrogated with Akt or PKCε inhibitor wortmannin or εV1–2. At a high level (1 mM), H<sub>2</sub>O<sub>2</sub> markedly aggravated the reperfusion injury and the oxidative stress but did not further enhance the RISK activation. In addition, 1 or 20 μM of H<sub>2</sub>O<sub>2</sub> PC did not alter cardioprotective effects of ischemic PC in postischemic contractile performance and protein oxidation. Our data suggest that the differential effects of H<sub>2</sub>O<sub>2</sub> are derived from a concentration-dependent wrestling between its detrimental stress and protective signaling.

*Cell Death and Disease* (2014) 5, e1297; doi:10.1038/cddis.2014.267; published online 19 June 2014

Reperfusion injury after acute myocardial ischemia is a complex phenomenon that consists of mechanical dysfunction and cell death.<sup>1,2</sup> Reactive oxidative species (ROS) are generated during the early phase of reflow and considered a major cause of reperfusion injury.<sup>3,4</sup> The mechanism may be related to the induction of calcium overload, membrane damage, and inflammation,<sup>5–9</sup> although these conclusions are still under debate.<sup>10,11</sup> Emerging evidence demonstrates that endoplasmic reticulum (ER) stress occurs during myocardial ischemia/reperfusion (I/R) and causes apoptosis via caspase-12.<sup>12,13</sup> Oxidative stress seems to be a direct activator of ER stress in the heart;<sup>14</sup> however, the precise interplay between ROS and ER stress during myocardial I/R injury has not yet been well established.

ROS also protect myocardium against I/R injury in preconditioning (PC) and postconditioning (PoC) scenarios via activating prosurvival reperfusion injury salvage kinase (RISK) pathways, especially through protein kinase B (PKB/Akt) and protein kinase Cε (PKCε),<sup>15</sup> with the downstream inhibition of glycogen synthase kinase-3β (GSK-3β).<sup>16–18</sup> However, the precise mechanisms for the dual roles of ROS have not yet been fully understood. Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), as the most stable form of ROS, has been intensively used to simulate severe oxidative damage in cardiomyocytes, cardiac myoblasts, and hearts,<sup>13,18–22</sup> and it also provides protection against I/R injury under certain conditions.<sup>8,11,13,20,21,23,24</sup> Pretreatment of isolated perfused rat hearts with 20 μM of H<sub>2</sub>O<sub>2</sub><sup>8,20</sup> or between 2 and 100 μM of

<sup>1</sup>Key Laboratory of Stem Cell Biology and Laboratory of Molecular Cardiology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) and Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China and <sup>2</sup>Division of Molecular Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

\*Corresponding author: H-T Yang, Key Laboratory of Stem Cell Biology and Laboratory of Molecular Cardiology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) and Shanghai Jiao Tong University School of Medicine (SJTUSM), 320 Yue Yang Road, Biological Research Building A, IHS Mail Box 115, Shanghai 200031, China. Tel: +86 21 54923280; Fax: +86 21 54923280; E-mail: htyang@sibs.ac.cn

<sup>3</sup>These authors contributed equally to this work.

**Abbreviations:** ROS, reactive oxygen species; ER, endoplasmic reticulum; I/R, ischemia/reperfusion; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; PC, preconditioning; PoC, postconditioning; RISK, reperfusion injury salvage kinase; LV, left ventricular; GRP78, glucose-regulated protein 78; IRE-1, inositol-requiring enzyme-1; ATF6, activating transcription factor-6; Xbp-1s, X-box-binding protein 1 splicing variant; TRAF2, TNF receptor-associated factor 2; p50-ATF6, activating transcription factor-6 cleaved 50 kDa fragment; p-PERK, phospho-protein kinase-like endoplasmic reticulum kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 4-PBA, 4-phenyl butyric acid; TM, tunicamycin; PKB, protein kinase B; PKCε, protein kinase Cε; WM, wortmannin; GSK-3β, glycogen synthase kinase-3β; DNP, 2, 4-dinitrophenylhydrazine; LVDP, left ventricle developed pressure; LVEDP, LV end-diastolic pressure; + dp/dt max, maximum rate of pressure development over time; – dp/dt max, maximum rate of pressure decay over time; IPC, ischemic preconditioning; Bal, balance


Received 09.1.14; revised 04.5.14; accepted 19.5.14; Edited by A Finazzi-Agrò

H<sub>2</sub>O<sub>2</sub><sup>11</sup> protects the heart against Ca<sup>2+</sup> paradox injury or I/R-induced calpain-dependent proteolysis, whereas in other studies the cardioprotection only appears at 2  $\mu$ M but not at 0.5, 1, 10 or 100  $\mu$ M of H<sub>2</sub>O<sub>2</sub> pretreatment.<sup>21,23</sup> These findings suggest that the concentration of ROS determines their different roles,<sup>25,26</sup> and ROS are cardioprotective at a low level but detrimental at a high level.<sup>27–29</sup> However, several questions remain unanswered: why do a number of animal and most clinical studies with antioxidants fail to convey cardioprotection;<sup>17,30</sup> why does the massive ROS burst that occurs at reperfusion not protect the I/R heart, though the ROS signaling in early reperfusion is crucial to PC- and PoC-induced cardioprotection;<sup>4,16,17,31</sup> and finally, why does the action of exogenous H<sub>2</sub>O<sub>2</sub> change drastically within lower concentrations? We recently found that the higher level of ROS production than the one elevated during early reperfusion following 30-min *ex vivo* ischemia is essential to intermittent hypobaric hypoxia- (a cardioprotective model<sup>32</sup>) induced cardioprotection. This occurs by efficiently activating the downstream prosurvival signaling pathways, and such effects are mimicked by 20  $\mu$ M H<sub>2</sub>O<sub>2</sub> PoC during the first 5 min of reperfusion.<sup>16</sup> Through these observations, we hypothesized that a moderate ROS level, higher than a level that initiates injurious insult in the early reperfusion stage, is required to trigger effectively cardioprotective signaling, whereas the endogenous ROS generated during early reperfusion following a short period of ischemia does not seem to reach the threshold to trigger efficient cardioprotection.

To address this hypothesis, our present study examined the concentration-dependent responses of ER stress and prosurvival kinases to H<sub>2</sub>O<sub>2</sub> PC and H<sub>2</sub>O<sub>2</sub> PoC, as well as their relationship. Our data demonstrate that a sufficient amount of H<sub>2</sub>O<sub>2</sub> is required to confer cardioprotection against I/R injury via the efficient activation of prosurvival kinases, whereas a low level of H<sub>2</sub>O<sub>2</sub> is insufficient to activate RISK pathways and deleterious through its induction of ER stress during myocardial I/R. These findings provide new insights into understanding the controversial roles of ROS in myocardial I/R injury and cardioprotection.

## Results


**Effects of H<sub>2</sub>O<sub>2</sub> PC and PoC on postischemic recovery of myocardial contractile function.** To determine the differential roles of H<sub>2</sub>O<sub>2</sub> during myocardial I/R injury, we examined the concentration-dependent effects of H<sub>2</sub>O<sub>2</sub> PC and PoC (Figure 1) on the postischemic recovery of myocardial contractile function in Langendorff-perfused rat hearts. H<sub>2</sub>O<sub>2</sub> PC and PoC significantly improved the postischemic recovery of left ventricle developed pressure (LVDP), LV end-diastolic pressure (LVEDP), and maximum rates of pressure development or decay over time ( $\pm dp/dt$  max) between the range of 10–100  $\mu$ M of H<sub>2</sub>O<sub>2</sub> with a peak around 20–30  $\mu$ M, whereas this protective effect was lost at 300  $\mu$ M and then completely suppressed at an excessive concentration (1 mM) of H<sub>2</sub>O<sub>2</sub> (Figure 2). Interestingly, a lower concentration of H<sub>2</sub>O<sub>2</sub> PC (1  $\mu$ M) aggravated the I/R-induced suppression of LVDP and  $\pm dp/dt$  max (Figures 2a, c, and d). These parameters also showed a



**Figure 1** Experimental protocols. Isolated rat hearts were subjected to 30 min of ischemia followed by 45 min of reperfusion (I/R control). The hearts were randomly exposed to various concentrations of H<sub>2</sub>O<sub>2</sub> (1, 3, 10, 20, 30, 100, 300, and 1000  $\mu$ M) for 5 min followed by a 5-min washout before ischemia in PC groups or for first 5 min of reperfusion in PoC groups. A PI3K inhibitor WM (100 nM), ER stress inhibitor 4-PBA (1 mM), inducer TM (2.5  $\mu$ g/ml), or PKC $\epsilon$  inhibitor  $\epsilon$ V1–2 (10  $\mu$ M) was perfused for 5 min with a 10-min washout before ischemia. IPC was induced by two cycles of 5-min ischemia (Is) before the onset of the index ischemia. At the end of the experiments, the hearts were used for western blot analysis. The equilibrium-perfused hearts with a corresponding period were collected as a balance control

suppression tendency at 1  $\mu$ M of H<sub>2</sub>O<sub>2</sub> PoC, but without statistical significance (Figures 2e, g, and h). These results suggest a quantitative threshold for H<sub>2</sub>O<sub>2</sub> to trigger effective cardioprotection against I/R-induced contractile dysfunction and this threshold being higher than that initiates the injury. The PoC data also support our previous finding<sup>16</sup> that the endogenous ROS generated during early reperfusion is lower than the threshold to induce cardioprotection against I/R-induced contractile dysfunction.<sup>16</sup>

**Concentration-dependent responses of prosurvival signaling pathways to H<sub>2</sub>O<sub>2</sub>.** To understand why relatively high levels of H<sub>2</sub>O<sub>2</sub> improve the recovery of myocardial function rather than aggravate the I/R injury, we examined the phosphorylation levels of Akt (Ser473), PKC $\epsilon$  (Ser729), and their downstream target GSK-3 $\beta$  (Ser9), whose phosphorylation inhibits the opening of mitochondrial permeability transition pore, a crucial event in reperfusion injury<sup>33</sup> that contributes to cardioprotection.<sup>34,35</sup> The total expression levels of Akt, PKC $\epsilon$ , and GSK-3 $\beta$  did not differ among groups, whereas their phosphorylation levels were significantly increased by I/R (Figure 3). The I/R-enhanced phosphorylation remained unchanged at lower concentrations (1–3  $\mu$ M) of H<sub>2</sub>O<sub>2</sub> but was further enhanced by H<sub>2</sub>O<sub>2</sub> over 10  $\mu$ M and reached a plateau around 30–100  $\mu$ M (Figure 3). These results suggest that sufficient amounts of H<sub>2</sub>O<sub>2</sub> are required




**Figure 2** Concentration-dependent effects of H<sub>2</sub>O<sub>2</sub> PC (left, a–d) and H<sub>2</sub>O<sub>2</sub> PoC (right, e–h) on the postischemic recovery of LV contractile function. (a and e) LVDP. (b and f) LVEDP. (c and g) +dp/dt max. (d and h) –dp/dt max. *N* = 4–7 each. Values are the mean ± S.E.M. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 versus control

to activate effectively the protective signaling, whereas the endogenous ROS generated during early reperfusion appear to be insufficient to trigger the RISK pathways.

**Effects of H<sub>2</sub>O<sub>2</sub> on the I/R-induced protein oxidation.** To identify the effects of H<sub>2</sub>O<sub>2</sub> on I/R-induced oxidative stress, we then examined the protein oxidation by measuring the 2, 4-dinitrophenylhydrazine (DNPH) derivatives of the common oxidation products protein carbonyls using western blot analysis. The content of myocardial protein carbonyls notably increased by I/R and was further enhanced by H<sub>2</sub>O<sub>2</sub> PC and PoC in a concentration-dependent manner (Figure 4). The increases were statistically significant between 10–1000 μM of H<sub>2</sub>O<sub>2</sub> in PC groups and 20–1000 μM in PoC groups, but

the increase by 1000 μM of H<sub>2</sub>O<sub>2</sub> at both PC and PoC was much higher than the 100 μM of H<sub>2</sub>O<sub>2</sub> and the lower (Figure 4).


**Concentration-dependent effects of H<sub>2</sub>O<sub>2</sub> on the I/R-induced ER stress.** ER stress has been shown to contribute to cardiomyopathy through three canonical pathways: inositol-requiring enzyme-1 (IRE-1), activating transcription factor-6 (ATF6), and phospho-protein kinase-like ER kinase (PERK).<sup>36</sup> To determine whether the low-level of ROS generated during early reperfusion is involved in myocardial I/R injury via the induction of ER stress, we analyzed the expression of ER stress markers predominant ER chaperone glucose-regulated protein 78 (GRP78),



**Figure 3** Concentration-dependent effects of H<sub>2</sub>O<sub>2</sub> PC (left) and PoC (right) on the activation of prosurvival kinases in I/R LV. Representative immunoblots and averaged data for phosphorylations of PKB/Akt (a), PKCε (b), and GSK-3β, (c). Bal, balance. *N* = 4 each. Values are the mean ± S.E.M. \**P* < 0.05 versus balance; #*P* < 0.05, ##*P* < 0.01, ###*P* < 0.001 versus I/R control

phosphorylated PERK, spliced X-box-binding protein-1 (Xbp-1s), and TNF receptor-associated factor 2 (TRAF2) for IRE-1 pathway, cleaved 50 kDa fragment of ATF6 (p50-ATF6), and prolonged ER stress marker cleaved caspase-12.<sup>6,7,12,36–38</sup> Myocardial I/R caused severe ER stress, characterized by marked increases in the phosphorylation of PERK at Thr980 and expressions of Xbp-1s, p50-ATF6 (Figure 5), GRP 78, TRAF2, and caspase-12 cleavage (Supplementary Figure S1). These increases were further enhanced by the low level of H<sub>2</sub>O<sub>2</sub> (1 μM) but reached a plateau between 3 and 300 μM of H<sub>2</sub>O<sub>2</sub> in both PC and PoC groups (Figure 5 and Supplementary Figure S1). Thus, the ER stress is already induced by the low-level H<sub>2</sub>O<sub>2</sub>, at which cardioprotection has not yet been efficiently induced.

**Low-level H<sub>2</sub>O<sub>2</sub> aggregated myocardial I/R injury via inducing ER stress.** We then examined the contribution of I/R- and low-level H<sub>2</sub>O<sub>2</sub>-induced ER stress to I/R injury by analyzing the postischemic myocardial contractile function with and without an ER stress inhibitor 4-phenyl butyric acid (4-PBA) and an ER stress inducer tunicamycin (TM; Figure 1). Inhibition of ER stress by 1 mM of 4-PBA significantly improved the postischemic recovery of LVDP, LVEDP, and +*dp/dt* max in I/R control and 1 μM of H<sub>2</sub>O<sub>2</sub> PC and PoC groups (Figures 6a–d). In addition, the H<sub>2</sub>O<sub>2</sub> PoC groups had a better postischemic recovery of LVDP and –*dp/dt* max, but made no difference compared with the I/R control when treated with 2.5 μg/ml of ER stress inducer TM (Figures 6a–d). The induction of ER stress by TM and



**Figure 4** Concentration-dependent effects of H<sub>2</sub>O<sub>2</sub> PC (left) and PoC (right) on myocardial protein oxidative stress during I/R injury. Representative immunoblots and averaged data of the DNP derivatives of protein carbonyls, common products of protein oxidation, in LV tissues from H<sub>2</sub>O<sub>2</sub> PC (a) and PoC (b) groups. Parallel gels were stained with Coomassie brilliant blue R250 dye as a control of protein loading. Bal, balance. *N* = 4 each. Values are the mean ± S.E.M. \**P* < 0.05 versus balance; #*P* < 0.05, ##*P* < 0.01, ###*P* < 0.001 versus I/R control, or as indicated on the figure

inhibition by 4-PBA were further confirmed by western blot analysis of the phosphorylation of PERK and the expressions of Xbp-1s, p50-ATF6 (Figure 6e), GRP78, TRAF2, and cleaved caspase-12 (Supplementary Figures S2a–d). The ER stress inhibitor 4-PBA but not inducer TM completely reversed I/R- or 1 μM of H<sub>2</sub>O<sub>2</sub> PC- and PoC-induced increases in the expression of ER stress markers (Figure 6e and Supplementary Figures S2a–d).

**Involvement of Akt and PKC $\epsilon$  activation in the cardioprotection induced by H<sub>2</sub>O<sub>2</sub>.** We next examined the contribution of Akt and PKC $\epsilon$  pathways to the moderate H<sub>2</sub>O<sub>2</sub>-protected postischemic contractile function by inhibiting phosphoinositide 3-kinases (PI3Ks) (upstream activator of Akt) with wortmmanin (WM) and PKC $\epsilon$  with  $\epsilon$ V1–2. WM (300 nM) and  $\epsilon$ V1–2 (10 μM) showed no effect on the postischemic recovery of LVDP, LVEDP, and  $\pm dp/dt$  max in the I/R group, but they diminished the protective effects of 20 μM H<sub>2</sub>O<sub>2</sub> PC and PoC (Figures 7a–d), suggesting that the cardioprotection induced by moderate H<sub>2</sub>O<sub>2</sub> depends on the activation of Akt and PKC $\epsilon$  pathways.


Because ER stress reached a plateau when moderate H<sub>2</sub>O<sub>2</sub> efficiently activated the RISK pathways (Figures 3 and 5), we asked whether the activation of RISK pathways limits ER stress development. Both WM and  $\epsilon$ V1–2 treatment enhanced the expression of ER stress markers and caspase-12 cleavage in the I/R group, but they did not further enhance the ER stress level seen in 20 μM H<sub>2</sub>O<sub>2</sub> PC and PoC group (Figure 7e and Supplementary Figures S2e–h). Thus, the I/R-activated RISK pathways contribute to the suppression of ER stress, but the ER stress seems to reach a maximal level under moderate H<sub>2</sub>O<sub>2</sub>.

**Effects of H<sub>2</sub>O<sub>2</sub> PC in the cardioprotection of classical IPC.** Ischemic precondition (IPC) is a well-established cardioprotective model where ROS has a crucial role

mediating the activation of prosurvival pathways.<sup>39,40</sup> To further determine the contribution of H<sub>2</sub>O<sub>2</sub> in the cardioprotective effects of IPC, we performed 1 μM or 20 μM of H<sub>2</sub>O<sub>2</sub> PC together with IPC (Figure 1) and compared their cardioprotective effects on each other. As seen in Figure 1, I/R-induced contractile dysfunction was aggravated by 1 μM of H<sub>2</sub>O<sub>2</sub> PC but improved by 20 μM of H<sub>2</sub>O<sub>2</sub> PC at a level comparable with those conferred by IPC (Supplementary Figures S3 a–d). Neither 1 nor 20 μM of H<sub>2</sub>O<sub>2</sub> PC had additive effects on the improved contractile function by IPC, although the IPC plus 1 μM of H<sub>2</sub>O<sub>2</sub> PC reversed the inhibition of 1 μM of H<sub>2</sub>O<sub>2</sub> PC on the postischemic contractile function (Supplementary Figures S3 a–d). Moreover, IPC showed a comparable level of protein oxidation with the 20 μM of H<sub>2</sub>O<sub>2</sub> PC and the IPC plus 1 or 20 μM of H<sub>2</sub>O<sub>2</sub> PC, whereas the I/R-increased protein oxidation remained unchanged in 1 μM of H<sub>2</sub>O<sub>2</sub> PC group (Figure 4 and Supplementary Figure S3e). These results suggest that 20 μM of H<sub>2</sub>O<sub>2</sub> PC may share similar cardioprotective mechanisms with IPC and may have a comparable level of ROS release during the induction phase of cardioprotection.

## Discussion

In this study, we described quantity-dependent and three-phase differential effects of H<sub>2</sub>O<sub>2</sub> in myocardial I/R injury and protection. We demonstrated that H<sub>2</sub>O<sub>2</sub> at the lower concentration aggravates I/R injury via the enhancement of I/R-induced ER stress before the sufficient activation of RISK pathways. H<sub>2</sub>O<sub>2</sub> PC and PoC at moderate concentrations, higher than a level that aggravated reperfusion injury, markedly induce cardioprotection via efficient activation of downstream prosurvival signaling pathways, whereas they induce a comparable level of ER stress as the lower concentration of H<sub>2</sub>O<sub>2</sub> PC or PoC. Furthermore, excessive




**Figure 5** Concentration-dependent effects of H<sub>2</sub>O<sub>2</sub> PC (left) and PoC (right) on ER stress in I/R LV. Representative immunoblots (a) and averaged data for the expression of ER stress markers, including (b) PERK phosphorylation, (c) Xbp-1s, and (d) p50-ATF6. GAPDH was used as an internal control. Bal, balance. *N* = 4 each. Values are the mean ± S.E.M. \*\**P* < 0.01, \*\*\**P* < 0.001 versus balance; #*P* < 0.05, ##*P* < 0.01 versus I/R control

H<sub>2</sub>O<sub>2</sub> exacerbates I/R injury when the activation of protective mechanisms reaches a plateau and fails to counteract severe nonspecific oxidative stress, but does not further increase ER stress. In addition, 20 μM H<sub>2</sub>O<sub>2</sub> PC-conferred cardioprotective effects are comparable with the IPC in postischemic contractile performance and protein oxidation. These results confirm and extend previous findings that H<sub>2</sub>O<sub>2</sub> PC and PoC can function as either injurious or protective stimuli determined by the wrestling between the detrimental and protective signaling roles triggered by different amounts of H<sub>2</sub>O<sub>2</sub>. Our data also indicate that the endogenous ROS generated during I/R is insufficient to trigger efficient cardioprotection. These findings provide a new angle to interpret the controversial roles of ROS in myocardial injury and protection.

We hypothesized that a moderate and sufficient increase of ROS during early reperfusion is required to activate effectively

the downstream protective signaling pathways, whereas the endogenous ROS generated during early reperfusion does not reach the threshold for efficient cardioprotection.<sup>16</sup> This hypothesis is supported by the observation that the higher level of ROS production, than that elevated by I/R during early reperfusion, is required for the IHH-induced cardioprotection by efficient activation of Akt and PKCε pathways.<sup>16</sup> The hypothesis is further supported by the data that I/R induces a noticeable activation of Akt and PKCε (Figure 3) but not enough to reach the threshold for efficient cardioprotection (Figures 7a–d). Moreover, the phosphorylation levels of Akt/PKB, PKCε, and GSK-3β are much higher in 10–300 μM of H<sub>2</sub>O<sub>2</sub> PC and PoC than those in I/R alone or in 1–3 μM of H<sub>2</sub>O<sub>2</sub> PC and PoC (Figure 3), whereas the inhibition of either Akt/PKB or PKCε activity completely reverses the middle concentration of H<sub>2</sub>O<sub>2</sub> PC- and PoC-afforded cardioprotection




**Figure 6** Involvement of ER stress in I/R-altered postischemic recovery of contractile function with and without the lower concentration of H<sub>2</sub>O<sub>2</sub> PC and PoC. Effects of ER stress inhibitor 4-PBA (1 mM) and inducer TM (2.5  $\mu\text{g}/\text{ml}$ ) on the postischemic recovery of LVDP (a), LVEDP (b), +dp/dt max (c), -dp/dt max (d), and the ER stress markers (e). (e) Top panels: representative immunoblots; lower panels: averaged immunoblots/data for PERK phosphorylation, Xbp-1s, and p50-ATF6. Bal, balance. *N* = 4–7 each. Values are the mean  $\pm$  S.E.M. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 versus balance; #*P* < 0.05, ##*P* < 0.01 versus I/R control; †*P* < 0.05, ††*P* < 0.01, †††*P* < 0.001 versus corresponding H<sub>2</sub>O<sub>2</sub> groups

(Figures 7a–d). Similar phenomena of moderate but not lower or higher concentrations of H<sub>2</sub>O<sub>2</sub> being cardioprotective were observed previously, although the concentrations vary with the treatment times and duration.<sup>21,23</sup> Thus, there is a quantitative threshold for H<sub>2</sub>O<sub>2</sub> to induce efficiently protective signaling pathways and thereby trigger sufficient cardioprotection against I/R injury. Furthermore, the enhancement of redox signaling by the addition of 10–100  $\mu\text{M}$  H<sub>2</sub>O<sub>2</sub> during the first 5 min of reperfusion, a phase that has been thought to generate excessive ROS,<sup>4,16,41,42</sup> induces a significant activation of the RISK pathway and cardioprotection (Figure 2). This is consistent with our previous observation of 20  $\mu\text{M}$  of H<sub>2</sub>O<sub>2</sub> PoC treated during the first 5 min of reperfusion<sup>16</sup> along with the report from Ytrehus *et al.*,<sup>25</sup> who treats with 1  $\mu\text{M}$  of H<sub>2</sub>O<sub>2</sub> during the first 30 min of reperfusion.

Although a lower concentration of H<sub>2</sub>O<sub>2</sub> is used in the latter, its protective effect may be due to a much longer treatment time as the activation of protective signaling by ROS accumulates with time.<sup>42</sup> Therefore, the endogenous ROS generated during early reperfusion in I/R hearts are insufficient to induce cardioprotection owing to the lower than threshold activated prosurvival signaling to trigger efficient cardioprotection. Higher levels of ROS are required for the efficient activation of protective signaling pathways, which results in cardioprotection. The data also explains why differential roles of exogenous H<sub>2</sub>O<sub>2</sub> within lower concentrations (0.5–100  $\mu\text{M}$ ) are seen in ischemic hearts,<sup>8,11,20–22</sup> as endogenous ROS levels vary with the extent and duration of myocardial I/R.

Interestingly, the induction of ER stress antecedes the activation of RISK pathways by H<sub>2</sub>O<sub>2</sub> in I/R hearts in a




**Figure 7** Activation of Akt and PKC $\epsilon$  contributes to moderate concentration of H<sub>2</sub>O<sub>2</sub> PC- and PoC-protected postischemic recovery of contractile function but does not affect the ER stress. (a–e) Effects of PI3K (upstream activator of Akt) and PKC $\epsilon$  inhibitors WM (300 nM) and  $\epsilon$ V1–2 (10  $\mu$ M) on the postischemic recovery of LVDP (a), LVEDP (b), + dp/dt max (c), – dp/dt max (d), and (e) the expression of ER stress markers. (e) Top panels: representative immunoblots; lower panels: averaged immunoblot data for PERK phosphorylation, Xbp-1s, and p50-ATF6. N = 4–7 each. Bal, balance. Values are the mean  $\pm$  S.E.M. \*P < 0.05, \*\*P < 0.01 < 0.001 versus balance; #P < 0.05, ##P < 0.01, ###P < 0.001 versus I/R control; †P < 0.05, ††P < 0.01, †††P < 0.001 versus corresponding H<sub>2</sub>O<sub>2</sub> groups

concentration-dependent manner (Figures 3 and 5 and Supplementary Figure S1). The I/R-induced myocardial contractile dysfunction is aggravated by the low level (1  $\mu$ M) of H<sub>2</sub>O<sub>2</sub> PC via ER stress activation but is reversed by ER stress inhibition (Figures 2 and 6). This is consistent with previous observations of the mediation of myocardial I/R injury<sup>6,7,12</sup> by ER stress and of the hypoxic or ischemic conditioning-induced cardioprotection via the attenuation of ER stress.<sup>21,43,44</sup> In addition, the I/R-induced ER stress is further enhanced by the low level (1  $\mu$ M) of H<sub>2</sub>O<sub>2</sub>, and it remains stable under higher levels of H<sub>2</sub>O<sub>2</sub> PC and PoC between 3 and 300  $\mu$ M (Figure 5 and Supplementary Figure S1). This stability may be caused by the counteractive effect of cardioprotective signaling pathways triggered by higher levels of H<sub>2</sub>O<sub>2</sub>. Our data indicate that I/R-activated PI3K and PKC $\epsilon$  inhibit the ER stress during I/R as both WM and  $\epsilon$ V1–2

treatment enhance the ER stress in the I/R group but not in the moderate H<sub>2</sub>O<sub>2</sub> PC and PoC groups (Figure 7e and Supplementary Figures S2e–h). The latter effect suggests that the induction of ER stress by 20  $\mu$ M H<sub>2</sub>O<sub>2</sub> may already reach the maximal limit. This is supported by the plateaus of ER stress seen between 3 and 300  $\mu$ M H<sub>2</sub>O<sub>2</sub> in both PC and PoC groups (Figure 5 and Supplementary Figure S1). The other possibility is that the protection against ER stress is mainly due to JAK2/STAT3 activation rather than that of PI3K/AKT.<sup>45</sup> The RISK pathway-mediated cardioprotection may be through a mechanism other than the salvage of an ER stress-induced injury and requires further investigation.

Another interesting finding is that the I/R-induced myocardial protein oxidation is significantly increased in a concentration-dependent manner when H<sub>2</sub>O<sub>2</sub> is between 10 or 20 and 1000  $\mu$ M H<sub>2</sub>O<sub>2</sub> either at PC or PoC (Figure 4), along





**Figure 8** Schematic model showing the mechanisms underlying dual roles of H<sub>2</sub>O<sub>2</sub> in myocardial I/R. The eventual outcome is a wrestling between the detrimental (straight line) and protective signaling (S-curve) roles of H<sub>2</sub>O<sub>2</sub>

with an efficient activation of the PI3K/AKT pathway that reaches a peak around 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> (Figure 3). H<sub>2</sub>O<sub>2</sub> PC at 100  $\mu$ M has been shown to counteract oxidative stress through an activated PI3K/AKT pathway;<sup>21,46</sup> however, this level surpasses the maximum for the RISK pathway activation and fails to offset further increased severe nonspecific oxidative stress.

IPC has been shown to stimulate the ROS release before I/R and prevented reperfusion injury via triggering the activation of prosurvival pathways in IPC.<sup>39,40</sup> This is further supported by our observations of no additive cardioprotective effects of 20  $\mu$ M H<sub>2</sub>O<sub>2</sub> PC to the IPC (Supplementary Figures S3a–d) and 20  $\mu$ M H<sub>2</sub>O<sub>2</sub> PoC to intermittent hypoxia.<sup>16</sup> These results also imply that IPC and intermittent hypoxia might release comparable levels of H<sub>2</sub>O<sub>2</sub> during the induction phase of cardioprotection with the moderate range of H<sub>2</sub>O<sub>2</sub> used here. This is supported by similar levels of protein oxidative responses between 20  $\mu$ M of H<sub>2</sub>O<sub>2</sub> PC and IPC (Supplementary Figure S3e) and comparable activation levels of Akt and PKC $\epsilon$  by 20  $\mu$ M of H<sub>2</sub>O<sub>2</sub> PoC and intermittent hypoxia-enhanced ROS production during early reperfusion.<sup>16</sup> Further studies need to be performed to confirm this possibility by providing direct evidence.

Based on the observations above, we propose a schematic model to explain the dual roles of ROS in myocardial I/R. As shown in Figure 8, the quantity of ROS determines their eventual effects through a wrestling between the detrimental (straight line) and protective signaling (S-curve) roles. Normally, ROS are generated at a low level and act as signaling molecules implicated in the physiologic control of the cell function in cardiomyocytes.<sup>35</sup> Myocardial I/R injury increases ROS production during early reperfusion, which is insufficient to trigger cardioprotection but already injurious through ER stress. Moderate amounts of ROS reach the threshold to trigger cardioprotection via the efficient activation of prosurvival kinases, and thereby overwhelm the detrimental

effects of ROS. When the heart is exposed to excessive ROS, the activation of protective mechanisms reaches a plateau and fails to counteract severe nonspecific oxidative stress.

In conclusion, our data demonstrate that the differential effects of H<sub>2</sub>O<sub>2</sub> are derived from a quantity-dependent wrestling between its detrimental and signaling roles. A sufficient amount of H<sub>2</sub>O<sub>2</sub> is required to confer cardioprotection against I/R injury via the efficient activation of prosurvival kinases, whereas a low level of H<sub>2</sub>O<sub>2</sub> is insufficient to trigger cardioprotection and deleterious through its induction of ER stress. The precise role of endogenous ROS in cardioprotection needs further investigation.

## Materials and Methods

**Animal care.** Animals used in this study were maintained in accordance with the *Guide for the Care and Use of Laboratory Animals* (Publication 85-23; National Institutes of Health, Bethesda, MD, USA), and all procedures were approved by the Institutional Review Board of Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and School of Medicine, Shanghai Jiao Tong University (Shanghai, China).

**I/R injury model in Langendorff-perfused rat hearts.** After rats were anesthetized with sodium pentobarbital (45 mg/kg, i.p.), the hearts were rapidly excised and perfused with Krebs–Henseleit solution at 37 °C using a Langendorff apparatus at a constant pressure of 80 mm Hg as described previously.<sup>16,47,48</sup> A water-filled latex balloon connected to a pressure transducer (Gould P23Db; AD Instrument, Sydney, NSW, Australia) was inserted into the LV cavity to achieve a stable LVEDP of 5–10 mm Hg during initial equilibration. After equilibration perfusion, the heart was subjected to 30 min of global no-flow ischemia followed by 45 min of reperfusion. LVDP and  $\pm dp/dt$  max were evaluated with PowerLab system (AD Instrument). IPC was induced by two cycles of 5-min ischemia before the onset of the index ischemia (30 min; Figure 1) as reported previously.<sup>49,50</sup>

**Experimental protocols.** Isolated hearts were randomly exposed to different concentrations of H<sub>2</sub>O<sub>2</sub> (1, 3, 10, 20, 30, 100, 300, and 1000  $\mu$ M) for 5 min, followed by a 5-min washout before ischemia in H<sub>2</sub>O<sub>2</sub> PC groups or for the first 5 min of reperfusion in H<sub>2</sub>O<sub>2</sub> PoC groups. PI3K inhibitor WM (300 nM; Millipore, Temecula, CA, USA),<sup>51</sup> PKC $\epsilon$  inhibitor  *$\epsilon$* V1-2 (10  $\mu$ M; Anaspec, Fremont, CA, USA),<sup>52</sup> ER stress inhibitor 4-PBA (1 mM; Sigma-Aldrich, St. Louis, MO, USA),<sup>53</sup> and ER stress inducer TM (2.5  $\mu$ g/ml; Sigma-Aldrich)<sup>54</sup> were perfused for 5 min with a 5-min washout before ischemia; hearts undergoing time-matched normal perfusion were used as controls, indicated as balance (Figure 1). At the end of the experiments, the hearts were rapidly removed and frozen in liquid nitrogen for western blot analysis.

**Western blot analysis.** Proteins were prepared as described previously.<sup>16</sup> Freeze-clamped LV tissues (200–300 mg) were homogenized briefly in 10 volumes of lysis buffer containing (in mM) 20 Tris-HCl (pH, 7.4), 150 NaCl, 2.5 EDTA, 50 NaF, 0.1 Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>, 1 Na<sub>3</sub>VO<sub>4</sub>, 1 PMSF, 1 DTT, 0.02% (v/v) protease cocktail (Sigma-Aldrich), 1% (v/v) Triton X-100, and 10% (v/v) glycerol. The homogenates were centrifuged two times at 20000  $\times$  g at 4 °C for 15 min, and the supernatants were saved as total proteins. Protein concentrations were determined by the BCA method. Equal amounts of proteins were separated by SDS-PAGE and transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA). Western blot analysis was performed under standard conditions with specific antibodies, including anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-PKC $\epsilon$  (Ser729), anti-PKC $\epsilon$ , anti-phospho-GSK-3 $\beta$  (Ser9), anti-GSK-3 $\beta$ , anti-PERK, anti-Xbp-1s, anti-p50-ATF6 (Abcam, London, UK), anti-TRAF2, anti-GRP78, anti-caspase-12 (Abcam), and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Antibodies were purchased from Cell Signaling (Danvers, MA, USA), unless noted otherwise. The immunoreaction was visualized using an enhanced chemiluminescent detection kit (Amersham, London, UK), exposed to X-ray film, and quantified by densitometry with a video documentation system (Gel Doc 2000; Bio-Rad).

**Protein oxidation analysis.** To evaluate the effects of H<sub>2</sub>O<sub>2</sub> conditioning on myocardial oxidative stress during I/R, we measured protein carbonyls, common products of protein oxidation,<sup>10</sup> in LV tissues homogenated in protein

lysis buffer without DTT. Protein carbonyls were measured using an immunoblot kit to detect the DNPH derivatization of protein carbonyls, as per the manufacturer's instruction (Cell Biolabs, San Diego, CA, USA).

**Statistical analysis.** Data were expressed as means  $\pm$  S.E.M. Statistical significance was determined using ANOVA or repeated-measures ANOVA for multiple comparisons or repeated measurements. Significant differences between two mean values were estimated using Student's *t*-test. A *P*-value  $< 0.05$  was considered statistically significant.

### Conflict of Interest

The authors declare no conflict of interest.

**Acknowledgements.** This study was supported by the Major State Basic Research Development Program of China (2012CB518203), National Natural Sciences Foundation of China (81170119), and National Science and Technology Major Project of China (2012ZX09501001). We thank Xiao-Long Cai for technical assistance in heart perfusions with the Langendorff technique.

- Hausenloy DJ, Yellon DM. Myocardial ischemia–reperfusion injury: a neglected therapeutic target. *J Clin Invest* 2013; **123**: 92–100.
- Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med* 2007; **357**: 1121–1135.
- Vanden HT, Becker LB, Shao ZH, Li CQ, Schumacker PT. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. *Circ Res* 2000; **86**: 541–548.
- Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. *J Biol Chem* 1988; **263**: 1353–1357.
- Shao D, Oka S, Brady CD, Haendeler J, Eaton P, Sadoshima J. Redox modification of cell signaling in the cardiovascular system. *J Mol Cell Cardiol* 2012; **52**: 550–558.
- Monassier JP. Reperfusion injury in acute myocardial infarction: from bench to cath lab. Part II: Clinical issues and therapeutic options. *Arch Cardiovasc Dis* 2008; **101**: 565–575.
- Monassier JP. Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part I: basic considerations. *Arch Cardiovasc Dis* 2008; **101**: 491–500.
- Petrosillo G, Di Venosa N, Pistolesi M, Casanova G, Tiravanti E, Colantuono G *et al*. Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemia–reperfusion: role of cardiolipin. *FASEB J* 2006; **20**: 269–276.
- Soliman D, Hamming Ks, Maternisz LC, Light PE. Reactive oxygen species directly modify sodium-calcium exchanger activity in a splice variant-dependent manner. *J Mol Cell Cardiol* 2009; **47**: 595–602.
- Milei J, Forcada P, Fraga CG, Grana DR, Iannelli G, Chiariello M *et al*. Relationship between oxidative stress, lipid peroxidation, and ultrastructural damage in patients with coronary artery disease undergoing cardioplegic arrest/reperfusion. *Cardiovasc Res* 2007; **73**: 710–719.
- Wang L, Lopaschuk GD, Clanachan AS. H<sub>2</sub>O<sub>2</sub>-induced left ventricular dysfunction in isolated working rat hearts is independent of calcium accumulation. *J Mol Cell Cardiol* 2008; **45**: 787–795.
- Liu XH, Zhang ZY, Sun S, Wu XD. Ischemic postconditioning protects myocardium from ischemia/reperfusion injury through attenuating endoplasmic reticulum stress. *Shock* 2008; **30**: 422–427.
- Zhang GG, Teng X, Liu Y, Cai Y, Zhou YB, Duan XH *et al*. Inhibition of endoplasmic reticulum stress by ghrelin protects against ischemia/reperfusion injury in rat heart. *Peptides* 2009; **30**: 1109–1116.
- Guo R, Ma H, Gao F, Zhong L, Ren J. Metallothionein alleviates oxidative stress-induced endoplasmic reticulum stress and myocardial dysfunction. *J Mol Cell Cardiol* 2009; **47**: 228–237.
- Lawrence KM, Kabir AM, Bellahcene M, Davidson S, Cao XB, McCormick J *et al*. Cardioprotection mediated by urocortin is dependent on PKCepsilon activation. *FASEB J* 2005; **19**: 831–833.
- Wang ZH, Chen YX, Zhang CM, Wu L, Yu Z, Cai XL *et al*. Intermittent hypobaric hypoxia improves posts ischemic recovery of myocardial contractile function via redox signaling during early reperfusion. *Am J Physiol Heart Circ Physiol* 2011; **301**: H1695–H1705.
- Hausenloy DJ, Wynne AM, Yellon DM. Ischemic preconditioning targets the reperfusion phase. *Basic Res Cardiol* 2007; **102**: 445–452.
- Tsutsumi YM, Yokoyama T, Horikawa Y, Roth DM, Patel HH. Reactive oxygen species trigger ischemic and pharmacological postconditioning: *in vivo* and *in vitro* characterization. *Life Sci* 2007; **81**: 1223–1227.
- Jaques-Robinson KM, Golfetti R, Baliga SS, Hadzimichalis NM, Merrill GF. Acetaminophen is cardioprotective against H<sub>2</sub>O<sub>2</sub>-induced injury *in vivo*. *Exp Biol Med (Maywood)* 2008; **233**: 1315–1322.
- Miyawaki H, Wang Y, Ashraf M. Oxidant stress with hydrogen peroxide attenuates calcium paradox injury: role of protein kinase C and ATP-sensitive potassium channel. *Cardiovasc Res* 1988; **37**: 691–699.
- Valen G, Starkopf J, Takeshima S, Kullisaar T, Vihalemm T, Kengsepp AT *et al*. Preconditioning with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) or ischemia in H<sub>2</sub>O<sub>2</sub>-induced cardiac dysfunction. *Free Radic Res* 1998; **29**: 235–245.
- Saotome M, Katoh H, Yaguchi Y, Tanaka T, Urushida T, Satoh H *et al*. Transient opening of mitochondrial permeability transition pore by reactive oxygen species protects myocardium from ischemia–reperfusion injury. *Am J Physiol Heart Circ Physiol* 2009; **296**: H1125–H1132.
- Blunt BC, Creek AT, Henderson DC, Hofmann PA. H<sub>2</sub>O<sub>2</sub> activation of HSP25/27 protects desmin from calpain proteolysis in rat ventricular myocytes. *Am J Physiol Heart Circ Physiol* 2007; **293**: H1518–H1525.
- Yaguchi Y, Satoh H, Wakahara N, Katoh H, Uehara A, Terada H *et al*. Protective effects of hydrogen peroxide against ischemia/reperfusion injury in perfused rat hearts. *Circ J* 2003; **67**: 253–258.
- Ytrehus K, Walsh RS, Richards SC, Downey JM. Hydrogen peroxide as a protective agent during reperfusion. A study in the isolated perfused rabbit heart subjected to regional ischemia. *Cardiovasc Res* 1995; **30**: 1033–1037.
- Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD. The mechanism by which the mitochondrial ATP-sensitive K<sup>+</sup> channel opening and H<sub>2</sub>O<sub>2</sub> inhibit the mitochondrial permeability transition. *J Biol Chem* 2006; **281**: 20801–20808.
- Sadoshima J. Redox regulation of growth and death in cardiac myocytes. *Antioxid Redox Signal* 2006; **8**: 1621–1624.
- Brennan JP, Southworth R, Medina RA, Davidson SM, Duchon MR, Shattock MJ. Mitochondrial uncoupling, with low concentration FCCP, induces ROS-dependent cardioprotection independent of KATP channel activation. *Cardiovasc Res* 2006; **72**: 313–321.
- Penna C, Perrelli MG, Pagliaro P. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. *Antioxid Redox Signal* 2013; **18**: 556–599.
- Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia–reperfusion injury. *Physiol Rev* 2008; **88**: 581–609.
- Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. *Basic Res Cardiol* 2008; **103**: 464–471.
- Yang HT, Zhang Y, Wang ZH, Zhou ZN. *Intermittent Hypoxia and Human Diseases*. Lei X, Tatiana VS (eds) Springer: London, pp 44–78, 2012.
- Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. *Biochem J* 1995; **307**(Part 1): 93–98.
- Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. *Circulation* 2008; **118**: 1915–1919.
- Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. *Cardiovasc Res* 2004; **61**: 461–470.
- Thorp EB. The myocardial unfolded protein response during ischemic cardiovascular disease. *Biochem Res Int* 2012; **2012**: 583170.
- Kim DS, Ha KC, Kwon DY, Kim MS, Kim HR, Chae SW *et al*. Kaempferol protects ischemia/reperfusion-induced cardiac damage through the regulation of endoplasmic reticulum stress. *Immunopharmacol Immunotoxicol* 2008; **30**: 257–270.
- Tao J, Zhu W, Li Y, Xin P, Li J, Liu M *et al*. Apelin-13 protects the heart against ischemia–reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. *Am J Physiol Heart Circ Physiol* 2011; **301**: H1471–H1486.
- Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. *Heart Fail Rev* 2007; **12**: 217–234.
- Facundo HT, Carreira RS, de Paula JG, Santos CC, Ferranti R, Laurindo FR *et al*. Ischemic preconditioning requires increases in reactive oxygen release independent of mitochondrial K<sup>+</sup> channel activity. *Free Radic Biol Med* 2006; **40**: 469–479.
- Vanden Hoek TL, Shao Z, Li C, Schumacker PT, Becker LB. Mitochondrial electron transport can become a significant source of oxidative injury in cardiomyocytes. *J Mol Cell Cardiol* 1997; **29**: 2441–2450.
- Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K *et al*. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. *J Biol Chem* 1999; **274**: 22699–22704.
- Liu Y, Yang XM, Iliodromitis EK, Kremastinos DT, Dost T, Cohen MV *et al*. Redox signaling at reperfusion is required for protection from ischemic preconditioning but not from a direct PKC activator. *Basic Res Cardiol* 2008; **103**: 54–59.
- Toth A, Nickson P, Mandl A, Bannister ML, Toth K, Erhardt P. Endoplasmic reticulum stress as a novel therapeutic target in heart diseases. *Cardiovasc Hematol Disord Drug Targets* 2007; **7**: 205–218.

45. Li Y, Zhu W, Tao J, Xin P, Liu M, Li J *et al*. Fasudil protects the heart against ischemia-reperfusion injury by attenuating endoplasmic reticulum stress and modulating SERCA activity: the differential role for PI3K/Akt and JAK2/STAT3 signaling pathways. *PLoS One* 2012; **7**: e48115.
46. Angeloni C, Motori E, Fabbri D, Malaguti M, Leoncini E, Lorenzini A *et al*. H<sub>2</sub>O<sub>2</sub> preconditioning modulates phase II enzymes through p38 MAPK and PI3K/Akt activation. *Am J Physiol Heart Circ Physiol* 2011; **300**: H2196–H2205.
47. Xie Y, Zhu WZ, Zhu Y, Chen L, Zhou ZN, Yang HT. Intermittent high altitude hypoxia protects the heart against lethal Ca<sup>2+</sup> overload injury. *Life Sci* 2004; **76**: 559–572.
48. Zhu WZ, Xie Y, Chen L, Yang HT, Zhou ZN. Intermittent high altitude hypoxia inhibits opening of mitochondrial permeability transition pores against reperfusion injury. *J Mol Cell Cardiol* 2006; **40**: 96–106.
49. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986; **74**: 1124–1136.
50. Iliodromitis EK, Lazou A, Kremastinos DT. Ischemic preconditioning: protection against myocardial necrosis and apoptosis. *Vasc Health Risk Manage* 2007; **3**: 629–637.
51. Sovershaev MA, Egorina EM, Andreassen TV, Jonassen AK, Ytrehus K. Preconditioning by 17beta-estradiol in isolated rat heart depends on PI3-K/PKB pathway, PKC, and ROS. *Am J Physiol Heart Circ Physiol* 2006; **291**: H1554–H1562.
52. Pravdic D, Sedlic F, Mio Y, Vladic N, Bienengraeber M, Bosnjak ZJ. Anesthetic-induced preconditioning delays opening of mitochondrial permeability transition pore *via* protein Kinase C-epsilon-mediated pathway. *Anesthesiology* 2009; **111**: 267–274.
53. Ayala P, Montenegro J, Vivar R, Letelier A, Urroz PA, Copaja M *et al*. Attenuation of endoplasmic reticulum stress using the chemical chaperone 4-phenylbutyric acid prevents cardiac fibrosis induced by isoproterenol. *Exp Mol Pathol* 2012; **92**: 97–104.
54. Okada K, Minamino T, Tsukamoto Y, Liao Y, Tsukamoto O, Takashima S *et al*. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. *Circulation* 2004; **110**: 705–712.



**Cell Death and Disease** is an open-access journal published by **Nature Publishing Group**. This work is licensed under a **Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License**. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

Supplementary Information accompanies this paper on Cell Death and Disease website (<http://www.nature.com/cddis>)